MiMedx Group Inc gross margin has been in long-term decline. The average rate of decline per year is -1.5%.
The historical rank and industry rank for MiMedx Group's Gross Margin % or its related term are showing as below:
MDXG'
s Gross Margin % Range Over the Past 10 Years
Min: 81.96 Med: 85.83 Max: 89.87
Current: 83.01
During the past 13 years, the highestGross Margin % of MiMedx Group was 89.87%. The lowest was 81.96%. And the median was 85.83%.
MDXG's Gross Margin % is ranked better than 77.04% of 736
companies
in the Biotechnology industry
Industry Median: 59.905
vs MDXG: 83.01
MiMedx Group had a gross margin of 84.06% for the quarter that ended in Dec. 2023 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for MiMedx Group was -1.50% per year.
MiMedx Group Gross Margin % Historical Data
The historical data trend for MiMedx Group's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of MiMedx Group's Gross Margin %
For the Biotechnology subindustry, MiMedx Group's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MiMedx Group's Gross Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MiMedx Group's Gross Margin % distribution charts can be found below:
* The bar in red indicates where MiMedx Group's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
MiMedx Group (NAS:MDXG) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
MiMedx Group had a gross margin of 84.06% for the quarter that ended in Dec. 2023 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
MiMedx Group Gross Margin % Related Terms
Thank you for viewing the detailed overview of MiMedx Group's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, MiMedx sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MDXG has been successfully added to your 